
    
      This study is being conducted to collect safety and immunogenicity data for the RVF vaccine,
      TSI-GSD 200, Lot 7, Run 2. Enrollment in this protocol is offered for personnel who enter
      areas where this virus is used in research or is endemic (an area where this disease process
      is found to occur frequently). Subjects who respond with a titer of >1:40 may participate for
      study duration. Rift Valley Fever Vaccine, Inactivated, Dried (TSI GSD 200) will be
      administered in 1.0-mL doses SQ in the upper outer aspect of the arm.
    
  